Imagion Biosystems Limited (IBXXF) Stock Price & Analysis
Imagion Biosystems Limited (IBXXF) — price $0.004 (0.00%), as of the Nov 19, 2026 trading session; market cap $3.21M.
Educational signal · not a buy or sell recommendation · How to read this
Imagion Biosystems Limited · IBXXF
Imagion Biosystems Limited is a medical imaging technology company focused on cancer detection and therapy monitoring using superparamagnetic relaxometry.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.004 | |
| Change on the day | 0.00% | |
| Market capitalisation | $3.21M | — |
| Shares traded on the day | 400.0K |
Price & events
Other perspectives
Council score for Imagion Biosystems (IBXXF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Imagion Biosystems (IBXXF), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Imagion Biosystems Limited (IBXXF) is the company analyzed here. In Q2 FY2026 it reported revenue of A$525,934 and net income of -A$2M. The market values it at $3.21M.
What do the latest results show for Imagion Biosystems (IBXXF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of A$525,934.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | A$525,934 | -A$2M | -A$0.0041 (diluted) |
| Q2 FY2025 | A$25,734 | -A$2M | -A$0.01 (diluted) |
| Q4 FY2024 | A$1M | -A$540,128 | -A$0.01 (diluted) |
What are the financial strengths and risks for Imagion Biosystems (IBXXF)?
Short answer · as of
The distress and quality screens read Piotroski F 3. Trailing ratios: ROE 165.9% · current ratio 0.16 · earnings yield -157.3%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held IBXXF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported IBXXF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Imagion Biosystems Stock: Key Questions Answered
These answers are editorial: 1 of these 1 answer is drawn from the IBXXF research dossier (written Mar 16, 2026 by gemini-2.0-flash). Figures in this section are not part of the source register.
How does Imagion Biosystems Limited navigate regulatory approval processes?
Imagion Biosystems Limited is currently navigating the regulatory approval process for its MagSense technology, which is in Phase I clinical trials.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 10 figures on this page — 7 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com